A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 901–1,000 of 1,138
Lessons From COBALT: Will the Bell Also Toll for Thee?
Vierling, J. M., & Pockros, P. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003061 · Cited by 1
Self-citationPrimary Biliary Cholangitis in Motion Meeting
Skellon, L. (2018) · EMJ Hepatology · doi:10.33590/emjhepatol/10310613 · Cited by 1
Emerging Treatment Strategies for Patients With Primary Biliary Cholangitis.
Moehlen, M. (2021) · PubMed Central · Cited by 2
Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
Ahn, D. (2020) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2020.25.2.107 · Cited by 1
Mells, G. F. (2019) · Medicine · doi:10.1016/j.mpmed.2019.09.012 · Cited by 1
Two new flavonoid glucosides from Penthorum chinense Pursh
Lu, S., Jiang, S., Feng, J., et al. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2426211 · Cited by 1
“…cholestatic liver disease, and several FXR agonists have been used in clinic for the treatment of cholestatic liver disease (markham and Keam 2016; nevens et al. 2016). our research group has spent over ten years on P. chinense research, including chemical demonstration and pharmacological…”
Mechanisms of Bile Formation and the Pathogenesis of Cholestasis
Karpen, S. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108918978.003 · Cited by 1
Passeri, D., Cerra, B., Carotti, A., Greco, F. A., Piermarini, S., Colliva, C., Liscio, P., Franco, F., Adorini, L., Erickson, M. R., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.202500960 · Cited by 2
Cazzagon, N., & Chazouillères, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_11 · Cited by 1
Recompensation in Cirrhosis: Biomarkers and Strategies
Ramírez-Quesada, W. E., Alvarado‐Tápias, E., Shalaby, S., & Hernández–Gea, V. (2025) · Seminars in Liver Disease · doi:10.1055/a-2542-9930 · Cited by 1
Bowlus, C. L., Nevens, F., Kowdley, K. V., Bonder, A., Capozza, T. A., Li, J., Nair, R., Trauner, M., & Jones, D. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70832 · Cited by 2
“In the overall population, the statistically significant reductions from baseline in ALP observed in OCA-treated patients in the DB phase [13] were sustained with continued treatment during the OLE (Figure 4A; Table S5).”
InfluentialSelf-citationRomeo, M., Nardo, F. D., Basile, C., Napolitano, C., Vaia, P., Martinelli, G., Gregorio, A. D., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120597 · Cited by 3
Anila, K. N., Saraswathy, S., Unnikrishnan, G., Balakrishnan, D., Mallick, S., Zackariah, N. M., Rajakrishnan, H., Gopinath, R., Krishnan, S., & Sudhindran, S. (2025) · Cureus · doi:10.7759/cureus.97915 · Cited by 1
“These results are consistent with the POISE trial [28] and other studies [29], which showed significant improvements in ALP and bilirubin in PBC patients treated with OCA.”
Liver and Gastrointestinal Pharmacology
Nguyen‐Lee, J., Nguyen, C., & Bagdasarjana, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-48110-6.00032-6 · Cited by 2
Dar, M. S., Fatima, T., Azhar, S. D., Rehman, Z., Affan, M., Saleem, Y. M., Ali, S., Athar, F., Ishaq, S., Ain, N. U., et al. (2025) · International Journal of Hepatology · doi:10.1155/ijh/8870546 · Cited by 1
Primary sclerosing cholangitis
Ahmad, J., & Grewal, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00019-5 · Cited by 1
Lipidome remodeling in primary biliary cholangitis
Rogalska, M., Rogalski, P., Andrzejuk, A., Błachnio-Zabielska, A. U., Zabielski, P., & Flisiak, R. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02887-5 · Cited by 1
“However, its effect on the lipid profile in PBC may be unfavorable, as it has been associated with reductions in HDL and total cholesterol levels and elevations in LDL levels [100, 101].”
Trampert, D. C. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.018 · Cited by 1
New drug: Obeticholic acid for primary biliary cholangitis
(2020) · Australian Prescriber · doi:10.18773/austprescr.2020.063 · Cited by 1
Primary biliary cholangitis and its association with other autoimmune diseases in a Mexican cohort
Cabello, E. A. R., & Montaño‐Loza, A. J. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.07.004 · Cited by 1
“The use of obeticholic acid was recently authorized for non-responder patients.(13) In addition, the combination therapy of UDCA plus bezafibrate was reported to have a higher complete biochemical response rate, compared with UDCA plus placebo.”
Patil, D., Patil, J., Patil, M., Girase, T., & Patel, K. (2023) · doi:10.3390/iocn2023-14506 · Cited by 1
“Additionally, FXR controls additional pathways with immediate anti-inflammatory and antifibrotic results [5].”
BackgroundZong, M., Xu, Y., Xing, F., Wang, D., Zheng, X.-R., Zhang, S., Zhan, J., Chen, J., Chen, G., Liu, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1762397 · Cited by 1
“Current first-line therapies for PBC, such as ursodeoxycholic acid (UDCA) and obeticholic acid, often fail to halt disease progression (Corpechot et al., 2000; Nevens et al., 2016).”
Zoubek, M. E. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210929mz · Cited by 1
Kim, W. K. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_14 · Cited by 3
Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision
Choi, G., Jesudian, A. B., & Saab, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09537-3 · Cited by 4
“…46% of patients with PBC who were treated with OCA 5–10 mg and 47% of patients treated with OCA 10 mg met the primary endpoint of a composite bio-chemical response (ALP 1.67 × ULN, ≥ 15% reduction in ALP from baseline, and total bilirubin ≤ ULN) compared with 10% in the placebo group [44, 52].”
InfluentialMartins, A., & Levy, C. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001076 · Cited by 3
Trivella, J. P., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00018-3 · Cited by 1
Russo, M. W. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09177-7 · Cited by 1
“In patients who are nonresponders or intolerant to UDCA, a decrease of ALP to 1.67 times the ULN or at least a 15% reduction from baseline was seen in 46% of the OCA-UDCA group compared with 10% in the placebo-UDCA group, p 0.001 [6].”
InfluentialBrunet, E., Hernández, L., Miquel, M., Sánchez‐Delgado, J., Dalmau, B., Valero, O., Vergara, M., & Casas, M. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.03.009 · Cited by 1
Chen, Y., Zhou, Y., Li, P., & Ding, B. (2025) · EngMedicine · doi:10.1016/j.engmed.2025.100070 · Cited by 2
Tse, C. S., Loftus, E. V., Raffals, L. E., Gossard, A. A., & Lightner, A. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14907 · Cited by 1
Emerging Therapeutics for Primary Biliary Cholangitis
Cho, E. J. (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2025.045 · Cited by 1
“4 In addition, liver-related events were also observed in patients at advanced stages.”
Tan, J. J.-R., Thiyagarajan, S., Tan, J., Ong, J., Lin, K., Tee, C. H. N., Tan, C. K., Tan, A. G. S., Ang, D., Ang, T. L., et al. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-0019 · Cited by 2
Lakshmanan, V., & Morris, L. (2025) · Cureus · doi:10.7759/cureus.94172 · Cited by 3
Elafibranor in the treatment of primary biliary cholangitis
Ergenç, İ., & Heneghan, M. A. (2025) · Future Rare Diseases · doi:10.1080/23995270.2025.2580910 · Cited by 2
Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators
Lamers, C., & Merk, D. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00076 · Cited by 1
Liu, J., Zhang, W., Xu, B., Ren, D., & Zhao, Y. (2025) · Cureus · doi:10.7759/cureus.89942 · Cited by 1
FXR–YAP signalling maintains biliary epithelial cell identity and preserves liver homeostasis
Sánchez-Sánchez, P., Wang, Z., Zagorac, S., Domínguez, M., Boskovic, J., Nair, A., Macías‐Camero, A., Villaseñor, A., Schwabe, R. F., & Djouder, N. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01521-z · Cited by 2
“…a semi-synthetic BA derivative and potent FXR agonist, developed to exploit the beneficial effects of FXR in hepatocytes, received accelerated approval as a second-line therapy for adults with PBC who are non-responders to ursodeoxycholic acid (UDCA), a BA lacking FXR agonist activity 14,15 .”
Primary Biliary Cholangitis, Liver Transplantation, and Hepatocellular Carcinoma: A Mini-review
Rawashdeh, B., Couillard, A. B., Rawshdeh, A., Aziz, H., Esteban, J. P., & Selim, M. A. (2022) · Gene Expression · doi:10.14218/ge.2022.00016 · Cited by 1
Burke, L., Flack, S., Jones, R. L., Aspinall, R., Thorburn, D., Jones, D. E., Braniff, C., Thain, C., Yeoman, A. D., Leithead, J., et al. (2022) · Cureus · doi:10.7759/cureus.25609 · Cited by 2
“67 times the upper limit of normal (ULN) after ≥12 months of treatment with UDCA 13-15 mg/kg/day [6].”
BackgroundSelf-citationNeues zur adjuvanten Therapie der Gallengangsatresie nach Kasai-Hepatoportoenterostomie
Madadi‐Sanjani, O., Hegen, B., Oh, J. S., Reinshagen, K., & Tomuschat, C. (2024) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-024-02093-6 · Cited by 1
Hohenester, S. D., & Beuers, U. H. (2017) · Der Internist · doi:10.1007/s00108-017-0287-z · Cited by 4
“Einheitlich empfohlen werden jährliche Ultraschalluntersuchungen zur Detektion von Raumforderungen der Gallenblase [1, 26, 28], wobei der Nachweis von Polypen >8mm zur Resektion führen sollte [28].”
BackgroundSelf-citationGulamhusein, A. F., & Jackson, N. D. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15588 · Cited by 1
Méndez‐Sánchez, N. (2018) · Minerva Medica · doi:10.23736/s0026-4806.18.05869-x · Cited by 1
Schregel, I., Steinmann, S., & Schramm, C. (2022) · Gastroenterologie up2date · doi:10.1055/a-1922-9264 · Cited by 1
Kobayashi, H., Sugiura, A., Koyama-Otagiri, M., Nimura, T., Kurasawa, Y., Shirakawa, H., & Joshita, S. (2025) · Cureus · doi:10.7759/cureus.83176 · Cited by 1
Jones, D. E., Combe, E., Knight, H., Laskier-Owens, V., Ren, S., Wright, T., Boing, E., & Pashley, A. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0206 · Cited by 1
“%) has been adopted as a primary efficacy outcome measure in clinical trials [12–14] .”
Self-citationUrsodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Gao, W., Li, Z., Chu, H., Yuan, H., Hu, L., Yao, L., Zhang, L. R., Wang, W., Lin, R., & Yang, L. (2022) · Springer eBooks · doi:10.1007/978-981-19-2615-0_6 · Cited by 1
Progressive Familial Intrahepatic Cholestasis
Khanna, R., & Gautam, V. (2022) · GI surgery annual · doi:10.1007/978-981-19-0828-6_5 · Cited by 2
Li, M., Chen, S., Li, S., Lv, T., Li, B., Shan, S., Li, M., Zeng, N., Wang, Q., Kong, Y., et al. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231224840 · Cited by 2
“31,32 However, our study focuses on patients with elevated levels of transaminases or IgG but did not meet the criteria for PBC with AIH features.”
BackgroundDhage, M. S., Ganamurali, N., Dhanasekaran, D., & Sabarathinam, S. (2021) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v11i2-s.4669 · Cited by 1
Contreras-Omaña, R., Velasco, J. A. V.-R., Castro‐Narro, G., Trujillo-Benavides, O. E., Zamarripa-Dorsey, F., Dorantes, Á. A. R., Muñoz-Espinosa, L. E., Aiza-Haddad, I., Castillo-Barradas, M., Reyes, E. C., et al. (2021) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2021.04.006 · Cited by 3
Primary biliary cholangitis review – new management strategies emerge
Gatley, E., Gogela, N. A., & Sonderup, M. W. (2025) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.2491
Neue Standards in der Behandlung der primären biliären Cholangitis
Vögelin, M., & Kremer, A. E. (2025) · Schweizer Gastroenterologie · doi:10.1007/s43472-025-00173-w
Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review
Malakar, S., Sood, N., Giri, S., & Samanta, A. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.120122
Rheumatologie und Hepatologie: Diagnostik und Therapie von autoimmunen Lebererkrankungen
Zipprich, A. (2019) · Aktuelle Rheumatologie · doi:10.1055/a-0885-9314
Hohenester, S. D., & Denk, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65701-x
Self-citationFibrate-Oca (FI-OCA) Study - a Global snapshot of PBC practice around the Globe
Ronca, V., Vincentis, A. D., Terracciani, F., et al. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.01.069
Self-citationObeticholic acid- an FXR agonist following living donor liver transplantation: Hope or hype?
(2024) · Archives of Health Science · doi:10.31829/2641-7456/ahs2024-8(1)-002
Orthotopic Liver Transplantation: Indications and Contraindications
Lai, Q., Iesari, S., & Lerut, J. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-05543-5_40-3
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1
Primary biliary cholangitis: progress and gaps in diagnosis and treatment
Komori, A. (2023) · Kanzo · doi:10.2957/kanzo.64.466
Magen/Darm- und Lebererkrankungen
Bock, K., & Seifert, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_12
Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
Ahn, D. (2020) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2020.75.5.246 · Cited by 2
Love, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-12399-2_9
New therapies for primary biliary cholangitis usher in a personalised approach to treatment
France, N. L. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01129-x
“…which are associated with longer transplant-free survival in patients with PBC, according to the results of a placebo-controlled phase 3 trial [11, 18] Elafibranor A dual PPARα/δ agonist [7, 13] It is not well understood how elafibranor works in patients with PBC, but it is known to inhibit bile…”
Cabello, E. A. R., & Montaño‐Loza, A. J. (2018) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.07.005 · Cited by 1
Primär biliäre Cholangitis (PBC)
Halilbasic, E., Munda, P., & Trauner, M. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21005-1.00055-x
Self-citationAnand, A. C. (2024) · Springer eBooks · doi:10.1007/978-981-99-9287-4_5
Kowdley, K. V. (2021) · PubMed
Self-citationHuang, S., Guo, J., Zhu, B., Ye, S., & Zhang, W. (2026) · Gastroenterology and Hepatology Research · doi:10.14218/ghr.2026.00002
Yang, M., Ren, H., Ren, X., Wen, P., Xie, J., Wan, X., Xu, K., Liu, L., Hou, W., Yang, Z., et al. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10224-5
Mohsen, M., Karkra, R., Medina‐Morales, E., Pagán-Busigó, J. E., Shamsian, E., Bebawy, M., Paracha, S., Patel, C., Sutariya, R., & Gaglio, P. J. (2026) · Livers · doi:10.3390/livers6020020
“More recently, peroxisome proliferator-activated receptor (PPAR) agonists, such as Seladelpar and Elafibranor, have been approved for use as second-line therapies and can be added to treatment regimens [10,12].”
Primär biliäre Cholangitis: Geänderter Name, neues Glück?
Kremer, A. E., & Beuers, U. H. (2018) · Die Gastroenterologie · doi:10.1007/s11377-018-0249-6
“Dabei waren ein persistierenderhöhterAP-Wertoberhalb des1,5-,1,67-,2-und3-fachendesoberen Normwerts und/oder erhöhte Bilirubinspiegel mit einer schlechteren Prognose assoziiert.”
BackgroundInfluentialSelf-citationLi, J., de Vries, H. D., Ustyantsev, K., Hovingh, M. V., Mulder, N. L., Havinga, R., Huijkman, N., Falcone, S., de Bruyn, K., Weersing, E., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101088 · Cited by 1
Carey, E. J., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/s1089-3261(18)30044-8 · Cited by 1
Guri, Y., & Kremer, A. E. (2024) · Schweizer Gastroenterologie · doi:10.1007/s43472-024-00132-x
Overlap Syndromes and Associated Immunoglobulin-G4-Related Liver Diseases
Malakar, S., Kumar, S., Roy, A., Giri, S., Rungta, S., Agarwal, M., Singh, A., Bassi, N., Samanta, A., Ghoshal, U. C., et al. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103564
(2000) · Time to knit · doi:10.1016/s1155-1976(21)43563-1
Magen-, Darm- und Lebererkrankungen
Bock, K., & Seifert, R. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_12
Microbiome-Derived Effectors and Convergent Host Pathways in Organ Injury and Fibrosis
D'Alessandro, V., Fujimoto, H., D’Alessandro‐Gabazza, C. N., Toda, M., Shah, R., Nishihama, K., Hataji, O., Gabazza, E. C., Leckband, D. E., Cann, I., et al. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl51062
Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective
Strasser, S. I., Thompson, A. J. V., Gupta, R., Lubel, J. S., French, J., Sacks, B., & Weltman, M. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70616
Self-citationApplication on Mesenchymal Stem Cells in the Treatment of Chronic Liver Disease
龙, 欢. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1371562
Pediatric Cholestatic Liver Disease: A Contemporary Review of Etiology, Diagnostics, and Management
Vather, M., Lee, J., & Vittorio, J. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00386-4
Ding, D., Ren, P., Guo, G., Liu, Y., Yang, C., Zheng, L., Jia, G., Deng, J., Sun, R., Wang, X., et al. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2023.01.005
Düll, M. M., & Kremer, A. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00031-8
HSD3B1 links ileal steroid metabolism to bile acid regulation in patients with prostate cancer
Fotouhi, N., Diaz, R., Alyamani, M., Chung, Y., West, G. A., Mukherjee, P. K., Abdshah, A., Burgess, R. A., Jatana, S., McKay, R. R., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci202725 · Cited by 2
The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex
Nguyen, H. H., & Swain, M. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.001
Burghart, L. (2023) · rheuma plus · doi:10.1007/s12688-023-00628-5
Tang, Y., Qi, F., Yu, Y., Fu, Y., & Zhu, P. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109158 · Cited by 1
Xiang, J., Yang, G., Ma, C., Wei, L., Wu, H., Tao, X., Jiang, L., Liang, Z., Kang, L., & yang, S. (2020) · doi:10.22541/au.159986113.39831843
Sini San ameliorates cholestatic liver injury by intrahepatically activating PPARα
Li, F., Li, X., Cai, Y., Li, Y., Yang, Y., Li, J., Wu, R., Luo, R., Sun, R., & Liu, R. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.07.005
Biologie des maladies cholestatiques chroniques de l’adulte
Lemoinne, S., & Chazouillères, O. (2017) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(17)30077-1
Terapias usuales y emergentes en colangitis biliar primaria
Díaz-Duque, J. C., Palacio-Valencia, V., Suárez-Meneses, J., Montaña-López, J. A., & Palacio-Sánchez, E. (2022) · Hepatología · doi:10.52784/27112330.156
Zheng, X., Zhang, Z., Jiao, X., Mu, M., Liu, A. Y., Huang, Y., Wu, W., Liao, C., Jiang, Y., Liang, W., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109721
Zhang, Z., Zheng, X., Dong, C., Li, P., Lin, Y., Sun, Z., Li, W., Liu, X., Li, J. J., Li, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03220 · Cited by 2
Recent Updates in the Prevention of Nonalcoholic Fatty Liver Disease
El‐Kassas, M., Awad, A., & Méndez‐Sánchez, N. (2023) · Gene Expression · doi:10.14218/ge.2022.00005s · Cited by 1
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.